



Post Authorisation Assessments

Amflee Combo 402 mg/ 361.8 mg Spot-on Solution for Extra Large Dogs Vm 01656/3043

•	08 March 2022	Minor change in the manufacturing process of the finished product.
•	22 April 2021	Renewal – UK as CMS.
•	27 August 2020	Change of specification(s) of a former non Pharmacopoeial active substance to comply with the Ph. Eur. or with a national pharmacopoeia of a Member State. Deletion of manufacturing site for an active substance.
•	12 December 2019	Minor change in the manufacturing process of the finished product.
•	07 October 2019	Change in the name of the manufacturer of the finished product.
•	24 September 2019	Addition of a secondary packaging site of the finished product.
•	22 August 2018	Change to a test procedure for the finished product.
•	22 February 2018	Change in contact details for local representative.
•	07 February 2018	Change in the RMS from UK to FR.
•	24 August 2017	Change in the invented name of the veterinary medicinal product from Amflee Combo 402 mg/ 361.8 mg Spot-on Solution for Extra Large Dogs to Fyperix Combo 402 mg/ 361.8 mg Spot-on Solution for Extra Large Dogs in FR & DE only.